Gene expression alterations in formalin-fixed, paraffin-embedded Barrett's esophagus and esophageal adenocarcinoma tissues

Cancer Biology and Therapy

Volumn 10, Issue 2, 2010, Pages 172-179

  Botelho, Natalia K ^a   Schneiders, Fiona I ^a   Lord, Sarah J ^a,b,c   Freeman, Araluen K ^a   Tyagi, Sonika ^d   Nancarrow, Derek J ^d   Hayward, Nicholas K ^d   Whiteman, David C ^d   Lord, Reginald V N ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Barrett's esophagus; Biomarkers; Esophageal adenocarcinoma; Esophageal neoplasms; SPARC; Tetraspanins

Indexed keywords

ALCOHOL DEHYDROGENASE; ALCOHOL DEHYDROGENASE 7; APC PROTEIN; CAUDAL TYPE HOMEOBOX 2 PROTEIN; CD151 ANTIGEN; CD9 ANTIGEN; CYCLIN B1; CYCLOOXYGENASE 2; DIHYDROPYRIMIDINE DEHYDROGENASE; EARLY GROWTH RESPONSE FACTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; GELATINASE B; GLUTATHIONE TRANSFERASE P1; INTERSTITIAL COLLAGENASE; MATRILYSIN; MESSENGER RNA; OSTEONECTIN; PAIRED LIKE HOMEODOMAIN 1 PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROTEIN; RETINOBLASTOMA PROTEIN; RETINOBLASTOMA PROTEIN 1; RETINOIC ACID RECEPTOR GAMMA; T LYMPHOCYTE IMMUNE REGULATOR 1 PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; TETRASPANIN; TETRASPANIN 1; TETRASPANIN 8; TRANSCRIPTION FACTOR ETS 1; UNCLASSIFIED DRUG;

ARTICLE; BARRETT ESOPHAGUS; CANCER TISSUE; CLINICAL ARTICLE; DOWN REGULATION; ENDOSCOPIC BIOPSY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS BIOPSY; FROZEN SECTION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MULTIPLEX POLYMERASE CHAIN REACTION; TISSUE FIXATION; UPREGULATION;

EID: 77955446623     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.2.12166     Document Type: Article

References (56)

1. Ronkainen J, Aro P, Storskrubb T, Johansson SE, Lind T, Bolling-Sternevald E, et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 2005; 129:1825-31.
2. Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage and age. J Natl Cancer Inst 2008;100:1184-7.
3. Reid BJ, Haggitt RC, Rubin CE, Roth G, Surawicz CM, Van BG, et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 1988;19:166-78.
4. Whiteman DC, Sadeghi S, Pandeya N, Smithers BM, Gotley DC, Bain CJ, et al. Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus. Gut 2008; 57:173-80.
5. De Ferrari L, Aitken S, De Ferrari L, Aitken S. Mining housekeeping genes with a Naive Bayes classifier. BMC Genomics 2006; 7:277.
6. Simon R. Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 2005; 23:7332-41.
7. Stanley KK, Szewczuk E. Multiplexed tandem PCR: gene profiling from small amounts of RNA using SYBR Green detection. Nucleic Acids Res 2005; 33:180.
8. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 2008; 100:1432-8.
9. Brabender J, Marjoram P, Salonga D, Metzger R, Schneider PM, Park JM, et al. A multigene expression panel for the molecular diagnosis of Barrett's esophagus and Barrett's adenocarcinoma of the esophagus. Oncogene 2004; 23:4780-8.
10. Mitas M, Almeida JS, Mikhitarian K, Gillanders WE, Lewin DN, Spyropoulos DD, et al. Accurate discrimination of Barrett's esophagus and esophageal adenocarcinoma using a quantitative three-tiered algorithm and multimarker real-time reverse transcription-PCR. Clin Cancer Res 2005; 11:2205-14.
11. Wang S, Zhan M, Yin J, Abraham JM, Mori Y, Sato F, et al. Transcriptional profiling suggests that Barrett's metaplasia is an early intermediate stage in esophageal adenocarcinogenesis. Oncogene 2006; 25:3346-56.
12. Lazo PA, Lazo PA. Functional implications of tetraspanin proteins in cancer biology. Cancer Science 2007;98:1666-77.
13. Huang CL, Liu D, Masuya D, Kameyama K, Nakashima T, Yokomise H, et al. MRP-1/CD9 gene transduction downregulates Wnt signal pathways. Oncogene 2004;23:7475-83.
14. Salmela MT, Karjalainen-Lindsberg ML, Puolakkainen P, Saarialho-Kere U. Upregulation and differential expression of matrilysin (MMP-7) and metalloelastase (MMP-12) and their inhibitors TIMP-1 and TIMP-3 in Barrett's oesophageal adenocarcinoma. Br J Cancer 2001; 85:383-92.
15. Sabo E, Meitner PA, Tavares R, Corless CL, Lauwers GY, Moss SF, et al. Expression analysis of Barrett's esophagus-associated high-grade dysplasia in laser capture microdissected archival tissue. Clin Cancer Res 2008; 14:6440-8.
16. Murray GI, Duncan ME, O'Neil P, McKay JA, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol 1998; 185:256-61.
17. Herszenyi L, Hritz I, Pregun I, Sipos F, Juhasz M, Molnar B, et al. Alterations of glutathione S-transferase and matrix metalloproteinase-9 expressions are early events in esophageal carcinogenesis. World J Gastroenterol 2007; 13:676-82.
18. Auvinen MI, Sihvo EI, Ruohtula T, Salminen JT, Koivistoinen A, Siivola P, et al. Incipient angiogenesis in Barrett's epithelium and lymphangiogenesis in Barrett's adenocarcinoma. J Clin Oncol 2002; 20:2971-9.
19. Brabender J, Lord RV, Metzger R, Park J, Salonga D, Danenberg KD, et al. Differential SPARC mRNA expression in Barrett's oesophagus. Br J Cancer 2003;89:1508-12.
20. Lord RV, Salonga D, Danenberg KD, et al. Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg 2000; 4:135-42.
21. Going JJ, Fletcher-Monaghan AJ, Neilson L, Wisman BA, van der Zee A, Stuart RC, et al. Zoning of mucosal phenotype, dysplasia and telomerase activity measured by telomerase repeat assay protocol in Barrett's esophagus. Neoplasia 2004; 6:85-92. (Pubitemid 38391951)
22. Wilson KT, Fu S, Ramanujam KS, Meltzer SJ. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 1998; 58:2929-34.
23. Zimmerman KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999;59:198-204. (Pubitemid 29062978)
24. Lord RV, Brabender J, Wickramasinghe K, DeMeester SR, Holscher A, Schneider PM, et al. Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma. Surgery 2005; 138:924-31.
25. Eda A, Osawa H, Satoh K, Yanaka I, Kihira K, Ishino Y, et al. Aberrant expression of CDX2 in Barrett's epithelium and inflammatory esophageal mucosa. J Gastroenterol 2003; 38:14-22. (Pubitemid 36267690)
26. Groisman GM, Amar M, Meir A, Groisman GM, Amar M, Meir A. Expression of the intestinal marker Cdx2 in the columnar-lined esophagus with and without intestinal (Barrett's) metaplasia. Mod Pathol 2004;17:1282-8.
27. Phillips RW, Frierson HF Jr, Moskaluk CA. Cdx2 as a marker of epithelial intestinal differentiation in the esophagus. Am J Surg Pathol 2003; 27:1442-7.
28. Lord RV, Park JM, Danenberg KD, DeMeester TR, Peters JH, Salonga D, et al. Increase in Vascular Endothelial Growth Factor and basic Fibroblast Growth Factor expression in Barrett's esophagus and adenocarcinomas of the esophagus and gastroesophageal junction. J Thorac Cardiovasc Surg 2003; 25:246-53.
29. Soslow RA, Nabeya Y, Ying L, Blundell M, Altorki NK. Acidic fibroblast growth factor is progressively increased in the development of oesophageal glandular dysplasia and adenocarcinoma. Histopath 1999; 35:31-7.
30. Soslow RA, Altorki NK, Yang G, Xie D, Yang CS. mdm-2 expression correlates with wild-type p53 status in esophageal adenocarcinoma. Mod Pathol 1999;12:580-6.
31. Lord RV, Tsai PI, Danenberg KD, Peters JH, DeMeester TR, Tsao-Wei DD, et al. Retinoic acid receptoralpha messenger RNA expression is increased and retinoic acid receptor-gamma expression is decreased in Barrett's intestinal metaplasia, dysplasia, adenocarcinoma sequence. Surgery 2001; 129:267-76.
32. Brabender J, Lord RV, Danenberg KD, Metzger R, Schneider PM, Park JM, et al. Increased c-myb mRNA expression in Barrett's esophagus and Barrett's-associated adenocarcinoma. J Surg Res 2001; 99:301-6.
33. Langer R, Specht K, Becker K, Ewald P, Bekesch M, Sarbia M, et al. Association of pretherapeutic expression of chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett carcinoma. Clin Cancer Res 2005; 11:7462-9.
34. Schneider S, Uchida K, Brabender J, Baldus SE, Yochim J, Danenberg KD, et al. Downregulation of TS DPD, ERCC1, GST-Pi, EGFR and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer. J Am Coll Surg 2005; 200:336-44.
35. Wang J, Qin R, Ma Y, Wu H, Peters H, Tyska M, et al. Differential gene expression in normal esophagus and Barrett's esophagus. J Gastroenterol 2009; 44:897-911.
36. Brabender J, Lord RV, Metzger R, Park J, Salonga D, Danenberg KD, et al. Role of retinoid X receptor mRNA expression in Barrett's esophagus. J Gastrointest Surg 2004; 8:413-22.
37. Sier CF, Verspaget HW, Griffioen G, Ganesh S, Vloedgraven HJ, Lamers CB. Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach. Gut 1993; 34:80-5.
38. Hourihan RN, O'Sullivan GC, Morgan JG. Transcriptional gene expression profiles of oesophageal adenocarcinoma and normal oesophageal tissues. Anticancer Res 2003; 23:161-5.
39. Brabender J, Lord RV, Wickramasinghe K, Metzger R, Schneider PM, Park JM, et al. Glutathione S-transferase-pi expression is downregulated in patients with Barrett's esophagus and esophageal adenocarcinoma. J Gastrointest Surg 2002; 6:359-67.
40. Coppola D, Schreiber RH, Mora L, Dalton W, Karl RC. Significance of Fas and retinoblastoma protein expression during the progression of Barrett's metaplasia to adenocarcinoma. Ann Surg Oncol 1999; 6:298-304. (Pubitemid 29221017)
41. Nekarda H, Schlegel P, Schmitt M, Stark M, Mueller JD, Fink U, et al. Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus. Clin Cancer Res 1998; 4:1755-63.
42. Barrett MT, Sanchez CA, Prevo LJ, Wong DJ, Galipeau PC, Paulson TG, et al. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 1999;22:106-9.
43. Kawakami K, Brabender J, Lord RV, Groshen S, Greenwald BD, Krasna MJ, et al. Hypermethylated APC DNA in Plasma and Prognosis of Patients With Esophageal Adenocarcinoma. J Natl Cancer Inst 2000;92:1805-11.
44. Geddert H, Heep HJ, Gabbert HE, Sarbia M, Geddert H, Heep HJ, et al. Expression of cyclin B1 in the metaplasia-dysplasia-carcinoma sequence of Barrett esophagus. Cancer 2002; 94:212-8.
45. Luthra MG, Ajani JA, Izzo J, Ensor J, Wu TT, Rashid A, et al. Decreased expression of gene cluster at chromosome 1q21 defines molecular subgroups of chemoradiotherapy response in esophageal cancers. Clin Cancer Res 2007; 13:912-9.
46. Dittmer J. The biology of the Ets1 proto-oncogene. Mol Cancer 2003; 2:29.
47. van Dekken H, Hop WC, Tilanus HW, Haringsma J, van der Valk H, Wink JC, et al. Immunohistochemical evaluation of a panel of tumor cell markers during malignant progression in Barrett esophagus. Am J Clin Pathol 2008; 130:745-53.
48. Bailey T, Biddlestone L, Shepherd N, Barr H, Warner P, Jankowski J. Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia- adenocarcinoma sequence: correlation with disease progression and dedifferentiation. Am J Path 1998; 152:135-44.
49. Washington K, Chiappori A, Hamilton K, Shyr Y, Blanke C, Johnson D, et al. Expression of beta-catenin, alpha-catenin and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas. Mod Pathol 1998;11:805-13.
50. Darlavoix T, Seelentag W, Yan P, Bachmann A, Bosman FT. Altered expression of CD44 and DKK1 in the progression of Barrett's esophagus to esophageal adenocarcinoma. Virchows Arch 2009; 454:629-37.
51. Murray L, Sedo A, Scott M, McManus D, Sloan JM, Hardie LJ, et al. TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort. Gut 2006; 55:1390-7.
52. Bian YS, Osterheld MC, Bosman FT, Fontolliet C, Benhattar J. Nuclear accumulation of beta-catenin is a common and early event during neoplastic progression of Barrett esophagus. Am J Clin Pathol 2000; 114:583-90.
53. Jankowski J, Murphy S, Coghill G, Grant A, Wormsley KG, Sanders DS, et al. Epidermal growth factor receptors in the oesophagus. Gut 1992; 33:439-43.
54. Rygiel AM, Milano F, Ten Kate FJ, Schaap A, Wang KK, Peppelenbosch MP, et al. Gains and amplifications of c-myc, EGFR and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus. Cancer Epidemiol Biomark Prev 2008;17:1380-5.
55. Pande AU, Iyer RV, Rani A, Maddipatla S, Yang GY, Nwogu CE, et al. Epidermal growth factor receptor-directed therapy in esophageal cancer. Oncology 2007;73:281-9.
56. Reid BJ, Li X, Galipeau PC, Vaughan TL. Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer 10:87-101.